The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with high unmet medical need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit. The company focuses on six major research areas: CardioMetabolic diseases, Central nervous system diseases, Immunology and Inflammation, Infectious diseases, Oncology and Respiratory diseases.

The goal of Boehringer Ingelheim in this consortium is to join forces in order to make the use of blood based biomarkers a standard in oncology clinical development.